Baricitinib or Tocilizumab? Treatment of Patients Hospitalized with Severe COVID-19∗

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)413-415
Number of pages3
JournalCritical care medicine
Volume51
Issue number3
DOIs
StatePublished - Mar 1 2023

Keywords

  • COVID-19
  • baricitinib
  • critical illness
  • immunomodulators
  • tocilizumab

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this